Scinai Immunotherapeutics Ltd（SCNI）の株式分析SCNIScinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Scinai Immunotherapeutics Ltd is currently not a strong buy due to its recent performance and financial instability. The stock is trading at $2.51, down 22.05% over the last five days and 65.59% year-to-date. Although the company reported a net income of $3.6 million in Q1 2026, this was primarily due to a non-cash gain, and the gross margin remains negative at -228.63%. The RSI is at 36.187, indicating potential oversold conditions, but the overall trend is bearish. The main risk is the Nasdaq notice regarding minimum bid price requirements, which could further impact the stock negatively.